Clinical Trials
9 trialsNCT05032183 2025-08-11
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00578292 2020-05-01
THALLO
Baylor College of Medicine
Phase NA Terminated
NCT00578461 2016-04-22
REGKINE
Baylor College of Medicine
Phase NA Terminated
NCT00578539 2016-04-22
REGALE
Baylor College of Medicine
Phase NA Terminated
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00002961 2013-10-16
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
Children's Hospital of Philadelphia
Phase 3 Terminated
NCT00126191 2013-05-23
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00473551 2011-12-19
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated